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Introduction
The present paper was born from the experience of cooperation 
among the Veterinarians and a Biostatistician (who are the Authors) 
in planning and analysing clinical studies. The cooperation started 
seven years ago and each study gave the opportunity to discuss both 
clinical and statistical issues. In this way the biostatistician became 
able to understand clinical research needs, in such a way to plan an 
adequate analysis, and veterinarians became able to interpret correctly 
statistical results, in such a way to evaluate results impact on their 
clinical practice. Several studies which concerned the evaluation of 
therapeutical strategies or the identification of potential risk factors, 
considering as end point the time elapsed from the beginning of the 
observation (e.g. date of the disease diagnosis, date of the surgery, 
starting date of pharmacological treatment) and the occurrence of an 
event which was related to the treatment failure or to the disease course 
were published and presented to meetings. Because much more debate 
arose around these studies than around other kinds of studies, the 
Authors decided to report some “critical aspects”. The Authors hope 
that reporting the critical aspects will be helpful to veterinarians, who 
have little experience on survival analysis, to evaluate and write results 
of prognostic studies. Since results of the statistical analysis should help 
clinicians in their “decision making process”, a correct methodology 
(by the Biostatistician) and a correct interpretation of model results (by 
the Veterinarian) is relevant. 
To show the statistical issues two literature data sets which were 
standard in survival analysis books, were used:
• Dataset 1: A multicentre clinical trial on remission maintenance of 
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children with acute Lymphoblastic leukaemia. The trial was published 
in [1] and data were reported at page 41 of the book [2]. 
• Dataset 2: A randomized clinical trial on advanced inoperable lung 
cancer (Veteran Administration Lung Cancer). Data were reported in 
the appendix A of the book [3].
Although data set concerned studies on “humans”, their peculiar 
characteristics allowed discussing some aspects which are common 
to survival analysis studies and, for readers who are confident with 
statistical packages, to give suggestions to perform the analysis by 
themselves.
Characteristics of Follow-Up Data, Common Statistical 
Approaches, Warnings and Some Proposed Improvements 
The commonly considered study end-points are: the time to 
occurrence of a single event (e.g. death, independently by the cause), 
time to occurrence of a composite event (e.g. all kinds of disease relapses 
and death), time to occurrence of a specific event strictly related to the 
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disease progression (e.g. death due to the disease). In order to perform 
a correct comparison among study results achieved on the same clinical 
condition it is important to detail which events were considered in the 
end points and how they were recorded. 
When a small sample of individuals is evaluated, follow-up time 
and events for each individual can be shown and discussed, making 
statistical analysis not strictly necessary to understand results. 
Otherwise, data should be synthesized by descriptive statistics (e.g. 
mean, median, percentages) and inferential procedures should be 
considered to draw conclusions on the study results. 
Follow-up data require descriptive and inferential statistical 
techniques which are specific for survival analysis. The techniques take 
into account peculiar characteristics of follow-up data: the study end-
point may not be observed for all subjects. Some subjects may be free of 
the event at the end of the observation period and some subjects may 
be lost to follow-up. The probability of being free of the event during 
follow-up is commonly estimated by the Kaplan-Meier method. When 
a putative categorical prognostic factor (e.g. lymph node metastasis) 
is analysed, the most frequent applied procedure is to estimate the 
event free survival curve for each category (e.g. lymph node metastasis 
present vs. lymph node metastasis absent) and to compare those 
event free survival curves by Log-Rank test. To draw conclusions on 
the prognostic role of the putative prognostic factor only the p-value 
of the test is usually considered. However, to assess the “clinical 
relevance” of the prognostic factor “clinically useful” measures should 
also be provided. These measures could be related to the difference 
between end-point probabilities at a given time (risk differences), 
to the ratio between end-point probabilities at a given time (relative 
risks) or alternatively, to the differences between end-point rates (rate 
differences or hazard differences) or to the ratio between end-point 
rates (rate ratios or hazard ratios).
When several clinical and pathological variables are analysed, 
Cox model is used to evaluate their joint prognostic role (multivariate 
analysis). Cox model is based on a specific assumption which must 
be tenable for the correctness of the results (i.e.: for each variable 
hazard ratio should be constant over follow-up time and this is named 
“proportional hazard” [2]). The “optimal” approach is to include all the 
variables into the model to identify which variables have a “significant” 
prognostic role. Unfortunately, this approach is not always possible. 
Literature suggests rules on the maximum number of regressors to be 
considered in multivariate analysis so to obtain reliable results [4-6]. The 
maximum number of regressors depends on the number of observed 
events rather than on the number of individuals in the study. Care is 
also needed for the coding of quantitative and qualitative (categorical) 
variables in order to avoid possible biased prognostic information. 
For qualitative variables (e.g. Tumour Stage with categories I, II, III) 
a category is chosen as “reference” (e.g. Stage I) and the following 
two hazard ratios: Stage II/Stage I and Stage III/Stage I are obtained 
by the exponent of the Cox regression coefficients. If Stage II and 
Stage III are not distinct (considered in the same category), only one 
hazard ratio is estimated: Stage II or Stage III/Stage I and the clinical 
interpretation of model results differ from those above cited for the 3 
Stage categories. To allow clinical usefulness of the model results, the 
categories should follow substantiated clinical criteria. For quantitative 
variables, a linear relationship between the logarithm of the hazard 
and the variable values is the simplest one. As an example, Age is a 
continuous variable and, under a linear relationship, the hazard ratio 
comparing the outcome of x years old subjects with the outcome of x+1 
years old subjects is the same whatever is the subject age x. Therefore, 
the logarithm of the hazard ratio comparing the outcome of 2 years 
old subjects with the outcome of 1-year old subjects is the same of the 
logarithm of the hazard ratio comparing the outcome of 12 years old 
subjects with the outcome of 11 years old subjects. However, the linear 
relationship could be improbable (e.g. the logarithm of the hazard ratio 
comparing the outcome of 2 years old subjects with the outcome of 
1-year old subjects could be less or greater than the logarithm of the 
hazard ratio comparing the outcome of 12 years old subjects with the 
outcome of 11 years old subjects). In such a case, a possible complexity 
of the shape for the relationship between continuous variables and 
model response should be investigated [7]. Statistical software outputs 
are tables containing regression coefficients, the standard errors 
and p-values. International guidelines suggest showing regression 
coefficients with the corresponding 95% confidence interval, because it 
is simpler to evaluate than standard errors [8-11].
A “statistically significant” result does not imply clinical usefulness. 
If the aim of the study is not only exploratory but it involves clinical 
decisions, useful insights are provided by a measure of the predictive 
performance of the model [12].
Data Presentation and Model Results 
The results of the statistical analysis retrieved for the two selected 
data sets were used to discuss the following issues: 
i) percentages of events, mean and median time are not always 
appropriate, ii) Log-Rank test: p-value is not a comprehensive 
evaluation and a related measure of prognostic association should be 
given, iii) interpretation of the statistical test: a p-value >0.05 does not 
mean that the variables do not have a prognostic role, iv) interpretation 
of Cox model results: hazard ratio, risk ratio, confidence intervals, v) 
coding of the variables in multivariate analysis and the maximum 
number of regressors allowed, vi) statistical significance and predictive 
ability.
Percentages of events, mean and median are not always appropriate
Dataset 1: A multicentre clinical trial on remission maintenance 
for children with acute Lymphoblastic leukaemia was designed to test 
whether patients who achieved complete remission using steroid could 
benefit from further treatment. Forty-two patients were randomized to 
receive maintenance therapy whit 6-mecaptourindine (6-MP; n=21) or 
placebo (n=21) [1,2]. 
Time to relapse (in weeks) of the two groups is reported as follows:
• Placebo 1,1,2,2,3,4,4,5,5,8,8,8,8,11,11,12,12,15,17,22,23 (all 
patients in placebo group had a relapse)
• 6-MP 6,6,6,6*,7,9*,10,10*,11*,13,16,17*,19*,20,22,23,25*,32*,32*,
34*,35* (some patients in 6-MP group were still in remission when the 
study was stopped and were considered as censored times, indicated 
by*). 
The placebo group: Percentage of events: 100*(21/21) =100%
All patients had a relapse, but from this data presentation no 
information was retrievable on time when 100% was reached. Results 
should be referred as “the cumulative probability of relapse at 23 week 
was 1.0 or “the probability of remission after 23 weeks is 0”.
The probability of remaining free from relapse was 0.762 at 3 weeks, 
0.571 at 6 weeks, and so on.
These are the estimates obtained by Kaplan-Meier method. The 
corresponding cumulative incidence curve can be easily obtained by 
1-relapse free survival probability (Figure 1).
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A relapse was observed for all patients in this group. Mean time 
to relapse and median time to relapse can be directly calculated from 
follow-up observation time: mean=8.67 weeks and median=8 weeks.
The 6-MP group 
Nine patients with relapse were observed: 100*(9/21) =42.86% and 
the percentage of patients still in remission was 57.1%. The cumulative 
probability of relapse at 35 weeks was not 0.4286 but it was 0.608. The 
probability of remaining in remission after 35 weeks was not 0.571 
but it was 0.392. It is matter of fact that the percentages previously 
calculated were wrong estimates. Why this difference? Twelve out of 
21 patients at the end of the study were still in remission and for 11 
patients the follow-up time was shorter than 35 weeks; we don’t know 
if they were still in remission at 35 weeks, we only know they were still 
in remission at 6,9,10,11,17,19,20,25,32,34 weeks, respectively.
The probability of relapse at a given time t can be calculated only on 
the group of patients who had not a relapse before t and whose status 
at t is known (i.e. at time t it is known if they had a relapse or if they 
were free from relapse). This group of patient is named “patients at 
risk” of relapse at time t. Patients whose status at time t is unknown 
(e.g. patients lost to follow-up before time t) cannot be considered in 
the group of patients “at risk” at time t. The cumulative probability of 
relapse at time t is obtained adding the probabilities of relapse for all 
times less or equal to t. 
For example at 6 weeks all 21 patients were at risk, 3 patients had 
relapse and the probability of relapse was 3/21=0.143. At 7 weeks a 
more complex situation was observed, 3 patients relapsed at 6 weeks 
and 1 patient who was still in remission at 6 weeks was no longer 
observed after 6 weeks thus patients at risk were 21-4=17. At 7 weeks, 
1 relapse was observed but the probability of relapse was not simply 
obtained by 1/17. In fact, a relapse at 7 weeks could be observed only if 
a patient was survived free from relapse till 7 weeks (1-3/21) thus the 
probability of relapse at 7 week was 1/17 x (1-3/21) and the cumulative 
probability of relapse at 7 week was
3/21+1/17 x (1-3/21) =0.193. The same procedure must be 
applied for all times and this was the criterion used for Kaplan-Meier 
estimation.
Median and mean time to relapse cannot be calculated directly 
from follow-up observation time, in fact time to relapse of patients who 
were still in remission at the end of the study was not known.
Median time to remission could be obtained from Kaplan-Meier 
estimation by searching the time corresponding to the relapse free 
probability of 0.5 (about 23 weeks). 
The comparison between survival curves: the interpretation of the 
test and a measure of association between variables and prognosis
When survival curves for groups of patients characterized by 
different modalities of a covariate are estimated by Kaplan-Meier 
method, the most common statistical test used is Log-Rank. Two 
hypotheses are formulated on the population from which the case 
series is a sample: the null hypothesis of equal survival experience of the 
groups to be compared (Ho) and the alternative hypothesis between 
the survival experiences of the groups to be compared (Ha). In the 
simplest case of two groups the hypotheses are formulated as follows: 
Ho: λ1(t)=λ2(t) and Ha: λ1(t)=θ λ2(t), where λ(t) is a “key” quantity in 
survival analysis, known as “hazard of event” (the event rate at time t). 
The alternative hypothesis is that the hazard of event for the group 1 is 
θ times the hazard of event for the group 2 [2]. 
When p-value of the Log-Rank test is < 0.05 the commonly 
reported conclusion is “the difference between the two group is 
statistically significant” (i.e. the null hypothesis is rejected with the 
planned probability =0.05. It is accepted to reject the null hypothesis 
with a probability of a wrong conclusion = 0.05). Unfortunately, when 
p-value is > 0.05, the result is sometime wrongly interpreted as “the 
survival experience of the two groups in the population is equivalent”. 
A statistical test cannot “demonstrate” the trueness of a statistical 
hypothesis. If the null hypothesis is rejected the results on the sample 
are a “support” of the alternative hypothesis, giving a strong evidence 
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Figure 1: The result supported the clinical hypothesis that the relapse free survival experience of the two treatment groups was different. The relevance of the 
difference could be evaluated from the plot of the estimated Kaplan-Meier curves. 
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that obtained results are “unlikely” to arise if the null hypothesis was 
true. If the null hypothesis is not rejected nothing can be stated on the 
evidence in favour of the null hypothesis. It is worth of note that p-value 
is not the most relevant criterion to evaluate differences between 
groups, it is also important that the observed differences are clinically 
relevant. A statistical test applied to a very large case series could 
provide a “statistically significant” result for a very small difference, 
which is not relevant from the clinical point of view [13]. On the other 
hand, a clinically relevant difference on a small case series could result 
as “not statistically significant “because of the low power of the test (i.e. 
the probability to correctly conclude that in the population the survival 
experience of the two groups are different). The observed difference 
could be “statistically significant” with a greater sample size, thus, in the 
situation of a clinically relevant difference with a p-value > 0.05 it is not 
correct to conclude on the equivalence of survival experience of the two 
groups in the population. A detailed discussion on the interpretation of 
statistical tests is reported on the Medical Statistical books ([14] among 
others) and in several tutorial papers ([15] among others).
For the leukaemia trial the result of the Log-Rank test was: Chi-
square= 16.8 and p-value= 4.19 x 10-5 (<0.00001). This result supported 
the clinical hypothesis that the relapse free survival experience of the 
two treatment groups was different. The relevance of the difference 
could be evaluated from the plot of the estimated Kaplan-Meier curves 
(Figure 1a) but a summary measure of treatment clinical impact is not 
directly provided by Log-Rank test.
As the hypothesis underlying Log-Rank test is based on the ratio 
between hazards of events, a possible measure of clinical impact is the 
hazard ratio, which is assumed to be constant over follow-up. Proposed 
approaches to estimate hazard ratio based on Log-Rank, have been 
evaluated by Kitchin and Mock [16]. A simpler method was to use Cox 
model in which only treatment (coded 0 if 6-MP and 1 if placebo) was 
included as explanatory variable.
The exponent of Cox model regression coefficient is the estimated 
hazard ratio and for treatment in leukaemia data set it was 4.801. 
This means that the hazard of relapse of placebo treated patients was 
about 5 times the hazard of relapse of 6-MP treated patients. Relevant 
estimates should be reported in association with the hazard ratio: the 
corresponding 95% confidence interval (for treatment leukaemia data 
set was 2.14-10.77). Although the null hypothesis of hazard ratio equal 
to 1 was rejected, the 95% confidence interval was wide, thus providing 
the information of a low precision of the estimate.
If the cumulative probability of relapse within a follow-up time (t) 
is called “risk”, the relative risk was the ratio between the estimated 
cumulative probabilities of relapse of the two treatment groups at that 
time [17,18]. It could be easily shown from Figure 1b that the risk 
ratio was not constant over time and it was different from hazard ratio 
(4.81). For example, at 6 weeks the risk ratio was 2.30, at ten weeks 
was 2.50, and at twelve weeks was 2.00, thus, in this case, it cannot be 
reported that the risk ratio was 4.81. 
Coding of the variables in multivariate analysis and the maximum 
number of regressors allowed 
Dataset 2: One-hundred and thirty-seven patients with advanced 
inoperable lung cancer were randomly assigned to two chemotherapy 
treatments: standard or experimental. Other additional variables were 
collected for each patient: Karnofsky Performance Score (0=bad, 
100=good), Time from Diagnosis to Randomization (months), Age 
(years), Prior Therapy (0=no, 1=yes), Cell Type (Squamous, Small, 
Adeno, and Large). Study primary end-point was the comparison of 
survival experience of the two treatment groups.
One-hundred and twenty-eight patients died (64 in both treatment 
groups) and nine were still alive at the end of follow-up period [3].
A first analysis could be performed only on the variable “treatment” 
because randomization should “guarantee” in probability the equal 
distribution of other variables in the two treatment groups.
Kaplan-Meier estimates for the two treatments groups are reported 
in Figure 2 and similar results for the two treatments were suggested. 
It was worth noticing that curves crossed and this could be a “hint” for 
the lack of proportional hazard.
Results of the test for the proportional hazard did not provide 
support to the lack of proportional hazard (p-value=0.07 for Kaplan-
Meier transform and p-value=0.14 for the identity transform). 
Results of the Cox model including only the variable treatment 
(coded as 0 for control and 1 for experimental): Hazard ratio =1.018, 
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Figure 2: Kaplan-Meier estimates for the two treatments groups . The curves crossed and this could be a “hint” for the lack of proportional hazard.
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95% confidence interval: 0.7144 -1.45, p-value=0.922. Regardless 
p-value, the hazard ratio was very near to 1.0 thus a very similar result 
was obtained for the two treatments.
The adjustment of treatment effect including into the model other 
variables retained as “clinically relevant” by previously published paper 
and/or previous knowledge of disease course is still debated in clinical 
trials literature [19-21]. However, to illustrate multivariate analysis, the 
other 5 variables in the dataset were included in the regression model to 
“adjust” treatment effect. Some variables were quantitative (Karnofsky 
Performance Score, Time from Diagnosis to Randomization, Age) and 
others were qualitative (Prior Therapy, Cell Type).
How to include the variables in the model: Concerning the 
quantitative variables the simplest approach is assuming a linear 
relationship between the variable and model response (logarithm of 
the hazard) thus the variable can be included in the model without data 
transformation. This approach could be inadequate and the possible 
nonlinear relationship needs to be tested. It is not simple and model 
results are difficult to be represented. If categorisation of the variable 
can be performed, under clinical consideration, model results are 
simple to evaluate. Nevertheless it can be taken into account that 
categorisation may result in a loss of prognostic information.
Categorical variables must be included into the model by generating 
dummy variables. One of the categories is chosen as “reference” and 
each dummy variable allows estimating the ratio between the hazard 
of the category and the hazard of the reference one. For a variable with 
k categories k-1 dummy variables are needed. Thus, for Treatment 
and Prior Therapy, having two categories, one dummy variable was 
generated: Standard Treatment and No Prior Therapy were chosen as 
reference. 
Cell Type was coded by 4 categories and three dummy variables 
were generated. Squamous was chosen as reference and the tree dummy 
variables allowed estimating the hazard ratio of Adeno vs. Squamous, 
Small vs. Squamous and Large vs. Squamous, respectively.
When Cox model is used for the multivariate analysis, it was 
recognized that a too-small ratio of events per variable (EPV) can 
affect the accuracy and precision of regression coefficients and their 
tests of statistical significance. It was suggested that 10 outcome events 
per predictor variable should be considered for the maximum number 
of regressors to be included into a multivariate regression model [4]. 
This rule was subsequently reconsidered suggesting a minimum of 5 
outcome events per predictor variable [5]. It is worth of note that the 
number of regressors may not be equal to the number of variables, in 
fact for categorical variables the number of corresponding dummy 
variables need to be counted.
In dataset 2, 128 deaths were observed thus a maximum of 13 
regressors (or a maximum of 26 regressors) should be included in 
multivariate Cox model. In the simplest model 8 regressors were 
considered: 5 for the categorical variables (1 dummy variable for 
Treatment, 1 dummy variable for Prior Therapy, 3 dummy variables 
for Cell Type) and 3 for the continuous variables (1 for Karnofsky 
Performance Score, 1 for Time from Diagnosis to Randomization, 
1 for Age). In case of nonlinear relationship between the logarithm 
of hazard ratio and continuous variable, for the latter 3 variables a 
greater number of regressors may be considered to model a possible 
complex shape. A simple way to face nonlinear relationship is to model 
variables as polynomials (e.g. including as regressors Age, Age2, Age3). 
An improvement of this approach giving more flexibility is the use 
of cubic splines (the range of the independent variable is subdivided 
using K breakpoints. Within each breakpoint a third order polynomial 
is considered and polynomials are then joined at breakpoints, called 
“knots”, to obtain a smoothed fit). The putative presence of nonlinear 
relationship for the continuous variables was tested including into the 
model regression cubic splines [22,23]. No evidence of nonlinear effects 
was found (p-value= 0.3145, 0.9134, 0.816 for Karnofsky Performance 
Score, Time from Diagnosis to Randomization and Age, respectively). 
Results of the multivariate Cox model are reported in Table 1.
With respect to the univariate analysis, the hazard ratio for the 
category “Treatment” was increased (from 1.018 to 1.343). The hazard 
ratio for Prior Therapy is near to 1, suggesting a small prognostic effect 
of the variable, regardless of statistical significance. A greater impact 
was observed for Cell Type where the hazard of death for patients with 
Adeno and Small cancer is more than double than the hazard of death 
for patients with Squamous cancer.
For continuous variables it is reported the hazard ratio for a “unit 
increase”: if the hazard ratio is less than 1.0, greater is the value of the 
variable more favourable is the prognosis, and vice-versa. Nevertheless 
it is common that estimated hazard ratios are near to 1.0 also for well-
known prognostic factors. Differently to the categorical variables, these 
results cannot be interpreted necessarily as a “small” prognostic impact. 
As an example, for Karnofsky Performance Score, the hazard ratio 
for a Score s+1 with respect to the Score s was 0.968. For a variable 
whose values ranged from 1 to 100 it was not expected that one unit 
increase of the Score could result in a “strength” prognostic impact. 
Variable Hazard Ratio 95% C.I. p-value
*
Treatment
0.157
Experimental / Standard 1.343 0.894-2.017
Karnofsky performance score
<0.00011 score increase
0.968 0.957-0.978
Time from diagnosis to 
randomization
0.9931 month increase
1.0001 0.982-1.018
Age
0.349
1 year increase 0.991 0.973-1.010
Prior therapy
0.758
Yes / No 1.074 0.681-1.694
Cell Type
Adeno / Squamous 3.307 1.834-5.965 <0.0001
Small / Squamous 2.367 1.380-4.060 0.002
Large / Squamous 1.494 0.858-2.600 0.156
Table 1: Results of the multivariate Cox model for dataset 2: Estimated Hazard 
ratios of death  and 95% confidence intervals.
Legend:  For categorical variables the notation  C/R  means  that HR is the ratio 
between the hazard of death for the category C and the hazard of death for the 
category R (the reference category).  e.g  3.307 is the ratio between the hazard of 
death for the category Adeno and the hazard of death for the category Squamous 
(reference category). 
For continuous variables the notation “1 unit increase” means that HR is the ratio 
between the hazard of death for the value of the variable j+1 and the hazard of 
death for the value of the variale j,  which is constant for all values of the variable.
e.g. 0.991 is the ratio between the hazard of death for age 31 and the hazard of 
death for age 30 which is equal to the ratio between the hazard of death for age 
51 and the hazard of death  for age 50 and which is equal to the hazard ratio of all 
comparisons between age j+1 and age j;    
95% C.I. : 95% confidence intervals;
*p -value of the Wald test.
Wald test was used to test the null hypotesis : Cox regression coefficient = 0 versus 
the alternative hypothesis:  Cox regression coefficient ≠ 0.
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In this case it could be preferable to show results for a “clinically 
meaningful” increase (e.g. 10 units increase: hazard ratio =0.720).
The predictive ability
The predictive ability of a Cox model result can be evaluated by the 
area under ROC curve for censored survival data, named “Harrell’s C 
index”. This index ranges between 0.5 (lack of predictive ability) and 
1 (perfect predictive ability) [12,22]. The estimated predictive ability 
was 0.74 for the Cox model results reported in Table 1. The model 
included both variable whose impact was “statistically significant” and 
variable whose impact was not “statistically significant”. Considering 
a model including only statistically significant variables (Karnofsky 
Performance Score and Cell Type), the model predictive ability was 
0.73, suggesting a negligible improve provided by the non-significant 
variables.
When Karnofsky Performance Score was excluded the predictive 
ability was 0.61 and when Cell Type was excluded the predictive ability 
was 0.71, suggesting a contribution of Karnofsky Performance Score 
greater than the contribution of Cell Type. When both the above 
mentioned variables were excluded the predictive ability was negligible 
(0.52).
Conclusion
The above considerations concern only the “most frequent discussed 
items”. We hope this paper could stimulate clinicians to read accurately 
statistical analysis results and avoiding to decide only on the basis of 
p-values. The cooperation between clinicians and biostatisticians could 
help clinicians to be more confident with statistical methods and could 
provide insights to evaluate the relevance of results taking into account 
also an adequate statistical analysis. 
The attitude of some clinicians is to privilege papers where data 
are presented with currently adopted statistical methods because they 
believe this is always the best approach. This is not necessarily true. 
In fact some studies could require alternative statistical modelling 
to have a deeper insight to the prognostic impact of therapeutical 
strategies. Unfortunately, statistical methods which are not currently 
adopted are sometimes considered with concerns irrespectively to the 
clinical relevance of results. The collaboration among clinicians and 
biostatistician can help to remove uncertainty in order to evaluate new 
approaches and to improve the planning and the analysis of clinical 
studies. 
Several other statistical issues on survival analysis could be faced; 
two examples are cited in the follow. 
In the considered examples only additive models are applied, 
avoiding to assume the possible presence of prognostic synergism 
between variables. In this case multivariate model must include specific 
“interaction” terms and results are more complex to show and to 
interpret. For this reason, interaction effects should be considered only 
under specific clinical hypothesis on their meaning. 
A further complication is when the focus is on the prognosis 
related to a specific unfavourable event in presence of the occurrence 
other events which avoid the observation of the event of interest. 
This condition is known as “competing risks”. A typical example of 
competing risks is death for the disease in presence of individuals 
whose cause of death can be related to the disease or not related to 
disease. The occurrence of a death not related to the disease avoids the 
observation of death related to the disease for that patient thus the two 
causes of death compete to be observed. In the presence of competing 
risks, Kaplan-Meier survival curves and Cox model are not appropriate 
to estimate the event probability during follow-up and to evaluate the 
prognostic effect of the covariates. Crude cumulative incidence curves 
and sub-distribution regression models are suitable for the analysis of 
competing risks data [24-26].
Analysis of competing risks was not considered in this paper as it is 
peculiar and it requires a separate processing. 
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